2(1H)-Isoquinolinepropanoic acid,6-[5-[3-cyano-4-(1-Methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3,4-dihydro-5-Methyl-,sodiuM salt(1:1)

GSK-2262167 is a potent S1P3-sparing and orally active S1P1 agonist. CGSK-2262167 is as efficacious as fingolimod in a collagen-induced arthritis model and shows excellent pharmacokinetic properties preclinically. Importantly, the selectivity of GSK-2262167 against S1P3 is responsible for an absence of cardiovascular signal in telemetered rats, even at high dose levels.